Related Posts
HSCA Comments to FDA Regarding FDA’s List of Public Health Focused Essential Medicines
February 5, 2021
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...
HSCA Comments on FDA Draft Guidance for Drug Supply Chain Security Act (DSCSA) Standards
November 9, 2022
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Comments on FDA “Risk Management Plans to Mitigate the Potential for Drug Shortages” Draft Guidance
August 22, 2022
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Response to FDA Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Draft Guidance
June 5, 2023
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Response to the U.S. Department of Commerce’s Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading traditional healthcare group purchasing organizations (GPOs), we appreciate the opportunity to provide comments to the U.S. Department of Commerce on its Section 232 national security investigation into pharmaceutical imports.
Click here to view the full response.